Qualigen Therapeutics (NASDAQ:QLGN) on Tuesday announced that it has signed definitive securities purchase agreements for sale of its 4,500 Series A-2 preferred shares, with a value of $1,000 per share, for gross proceeds of $4.5 million. The shares of Series A-2 Preferred Shares are initially convertible into an aggregate of 1,236,263 common shares of the Company at a conversion price of $3.64 per share. The offering is expected to close on or about November 19, 2024. QLGN -4.12% premarket to $3.49. Source: Press Release
More on Qualigen Therapeutics
Qualigen Therapeutics announces CEO and CFO retirements Financial information for Qualigen Therapeutics